Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $23.50 Consensus Target Price from Brokerages

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have been given an average recommendation of “Hold” by the ten brokerages that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $23.50.

A number of analysts recently issued reports on PCRX shares. Barclays decreased their price objective on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 12th. Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Pacira BioSciences in a research report on Friday, November 8th. Jefferies Financial Group boosted their price objective on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. HC Wainwright reissued a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a report on Wednesday, December 4th. Finally, Royal Bank of Canada upped their price target on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th.

Pacira BioSciences Stock Down 0.8 %

Shares of NASDAQ PCRX opened at $19.65 on Wednesday. The business’s fifty day moving average price is $17.91 and its 200-day moving average price is $18.40. Pacira BioSciences has a one year low of $11.16 and a one year high of $35.95. The stock has a market capitalization of $907.30 million, a PE ratio of -9.68 and a beta of 0.80. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Institutional Trading of Pacira BioSciences

Several large investors have recently bought and sold shares of the company. Pacer Advisors Inc. boosted its position in shares of Pacira BioSciences by 129.4% in the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock worth $74,681,000 after purchasing an additional 2,799,434 shares in the last quarter. Fort Washington Investment Advisors Inc. OH bought a new position in shares of Pacira BioSciences during the second quarter valued at $13,240,000. Assenagon Asset Management S.A. raised its position in shares of Pacira BioSciences by 314.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock worth $8,324,000 after purchasing an additional 419,656 shares during the last quarter. Doma Perpetual Capital Management LLC boosted its stake in Pacira BioSciences by 71.8% in the 2nd quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock worth $28,632,000 after purchasing an additional 418,321 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in Pacira BioSciences by 269.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock valued at $5,955,000 after purchasing an additional 288,662 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.